arginine has been researched along with eplerenone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Angel, A; Chernichovski, T; Grupper, A; Hod, T; Kazan, S; Kliuk-Ben Bassat, O; Naveh, S; Schwartz, IF; Shashar, M; Weinstein, T | 1 |
1 review(s) available for arginine and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for arginine and eplerenone
| Article | Year |
|---|---|
Mineralocorticoid receptor blockade improves arginine transport and nitric oxide generation through modulation of cationic amino acid transporter-1 in endothelial cells.
Topics: Arginine; Biological Transport; Cationic Amino Acid Transporter 1; Eplerenone; Glycosylation; Human Umbilical Vein Endothelial Cells; Humans; Mineralocorticoid Receptor Antagonists; Nitric Oxide; Phosphorylation; Protein Kinase C-alpha; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone | 2018 |